LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: dbgap2x: an R package to explore and extract data from the database of Genotypes and Phenotypes (dbGaP).

    Versmée, Grégoire / Versmée, Laura / Dusenne, Mikaël / Jalali, Niloofar / Avillach, Paul

    Bioinformatics (Oxford, England)

    2019  Volume 36, Issue 4, Page(s) 1305–1306

    Abstract: Summary: Based on the Genomic Data Sharing Policy issued in August 2007, the National Institutes of Health (NIH) has supported several repositories such as the database of Genotypes and Phenotypes (dbGaP). dbGaP is an online repository that provides ... ...

    Abstract Summary: Based on the Genomic Data Sharing Policy issued in August 2007, the National Institutes of Health (NIH) has supported several repositories such as the database of Genotypes and Phenotypes (dbGaP). dbGaP is an online repository that provides access to large-scale genetic and phenotypic datasets with more than 1000 studies. However, navigating the website and understanding the relationship between the studies are not easy tasks. Moreover, the decryption of the files is a complex procedure. In this study we propose the dbgap2x R package that covers a broad range of functions for searching dbGaP studies, exploring the characteristics of a study and easily decrypting the files from dbGaP.
    Availability and implementation: dbgap2x is an R package with the code available at https://github.com/gversmee/dbgap2x. A containerized version including the package, a Jupyter server and with a Notebook example is available at https://hub.docker.com/r/gversmee/dbgap2x.
    Supplementary information: Supplementary data are available at Bioinformatics online.
    MeSH term(s) Databases, Factual ; Genomics ; Genotype ; Plant Extracts ; Software
    Chemical Substances Plant Extracts
    Language English
    Publishing date 2019-09-06
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1422668-6
    ISSN 1367-4811 ; 1367-4803
    ISSN (online) 1367-4811
    ISSN 1367-4803
    DOI 10.1093/bioinformatics/btz680
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2374: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.

    Dietrich, Jorg / Versmee, Laura / Drappatz, Jan / Eichler, April F / Nayak, Lakshmi / Norden, Andrew / Wong, Eric / Pisapia, Michelle R / Jones, SooAe S / Gordon, Amanda B / Chabner, Bruce A / Hochberg, Fred / Batchelor, Tracy T

    The oncologist

    2020  Volume 25, Issue 9, Page(s) 747–e1273

    Abstract: Lessons learned: The findings from this study using monotherapy with pemetrexed in a pretreated patient population are, overall, encouraging. Unlike high-dose methotrexate, which requires several days of inpatient hospitalization, pemetrexed is ... ...

    Abstract Lessons learned: The findings from this study using monotherapy with pemetrexed in a pretreated patient population are, overall, encouraging. Unlike high-dose methotrexate, which requires several days of inpatient hospitalization, pemetrexed is relatively easy to administer in the outpatient setting and remains a viable treatment option in this patient population. The maximum tolerated dose of pemetrexed administered (900 mg/m
    Background: There is currently no standard salvage treatment for patients with relapsed/refractory central nervous system (CNS) lymphoma (CNSL). We report the results of a phase I study of pemetrexed, an antifolate drug with broader activity than methotrexate (MTX). We provide the safety, tolerability, and maximum tolerated dose (MTD) of pemetrexed in patients with recurrent CNSL.
    Methods: Through October 2015, 17 patients with relapsed/refractory CNSL received pemetrexed every 2 weeks with the first cohort receiving 600 mg/m
    Results: Seventeen patients were evaluable with a median age of 63.7 years. Main adverse events included fatigue (82.4%), anemia (82.4%), and neutropenia (70.6%). The MTD was established at 900 mg/m
    Conclusion: Pemetrexed administered at 900 mg/m
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Central Nervous System ; Humans ; Lymphoma/drug therapy ; Lymphoma, Non-Hodgkin/drug therapy ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Pemetrexed/therapeutic use
    Chemical Substances Pemetrexed (04Q9AIZ7NO)
    Language English
    Publishing date 2020-07-01
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Multicenter Study
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1634/theoncologist.2020-0489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.

    Etienne, Gabriel / Faberes, Carole / Bauduer, Fréderic / Adiko, Didier / Lifermann, François / Dagada, Corinne / Lenoir, Caroline / Schmitt, Anna / Klein, Emilie / Fort, Marie-Pierre / Bijou, Fontanet / Turcq, Beatrice / Robbesyn, Fanny / Durrieu, Françoise / Versmée, Laura / Madene, Samia / Moldovan, Marius / Katsahian, Sandrine / Charles-Nelson, Anais /
    Lascaux, Axelle / Mahon, François-Xavier / Dulucq, Stéphanie

    Cancer medicine

    2021  Volume 10, Issue 11, Page(s) 3635–3645

    Abstract: Background: Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic phase chronic myeloid leukemia (CP-CML) patients who had achieved a sustained deep molecular response. Based on the results of discontinuation trials, recommendations ... ...

    Abstract Background: Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic phase chronic myeloid leukemia (CP-CML) patients who had achieved a sustained deep molecular response. Based on the results of discontinuation trials, recommendations regarding patient selection for a treatment-free remission (TFR) attempt had been proposed. The aims of this study were to evaluate the rate of patients eligible for TKI discontinuation and molecular recurrence-free survival (MRFS) after stop according to recommendations.
    Methods: Over a 10-year period, newly diagnosed CP-CML patients and treated with first-line TKI in the nine French participating centers were included. Eligibility to treatment discontinuation and MRFS were analyzed and compared according to selection criteria defined by recommendations and first-line treatments.
    Results: From January 2006 to December 2015, 398 patients were considered. Among them, 73% and 27% of patients received imatinib or either second or third generation tyrosine kinase inhibitors as frontline treatment, respectively. Considering the selection criteria defined by recommendations, up to 55% of the patients were selected as optimal candidates for treatment discontinuation. Overall 95/398 (24%) discontinued treatment. MRFS was 51.8% [95% CI 41.41-62.19] at 2 years and 43.8% [31.45-56.15] at 5 years. Patients receiving frontline second-generation TKI and fulfilling the eligibility criteria suggested by recommendations had the lowest probability of molecular relapse after TKI stop when compare to others.
    Conclusion: One third of CP-CML patients treated with TKI frontline fulfilled the selection criteria suggested by European LeukemiaNet TFR recommendations. Meeting selection criteria and second-generation TKI frontline were associated with the highest MRFS.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Female ; France ; Fusion Proteins, bcr-abl/analysis ; Guidelines as Topic ; Humans ; Imatinib Mesylate/therapeutic use ; Leukemia, Myeloid, Chronic-Phase/drug therapy ; Leukemia, Myeloid, Chronic-Phase/genetics ; Male ; Middle Aged ; Patient Selection ; Progression-Free Survival ; Protein Kinase Inhibitors/therapeutic use ; Recurrence ; Remission Induction ; Withholding Treatment/statistics & numerical data ; Young Adult
    Chemical Substances Protein Kinase Inhibitors ; Imatinib Mesylate (8A1O1M485B) ; Fusion Proteins, bcr-abl (EC 2.7.10.2)
    Language English
    Publishing date 2021-05-14
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 2659751-2
    ISSN 2045-7634 ; 2045-7634
    ISSN (online) 2045-7634
    ISSN 2045-7634
    DOI 10.1002/cam4.3921
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.

    Etienne, Gabriel / Dulucq, Stéphanie / Bauduer, Fréderic / Adiko, Didier / Lifermann, François / Dagada, Corinne / Lenoir, Caroline / Schmitt, Anna / Klein, Emilie / Madene, Samia / Fort, Marie-Pierre / Bijou, Fontanet / Moldovan, Marius / Turcq, Beatrice / Robbesyn, Fanny / Durrieu, Françoise / Versmée, Laura / Katsahian, Sandrine / Faberes, Carole /
    Lascaux, Axelle / Mahon, François-Xavier

    Cancers

    2020  Volume 12, Issue 9

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2020-09-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers12092521
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top